NEWTON, Mass.--(BUSINESS WIRE)--Jan. 12, 2006--Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in developing and commercializing pharmacogenomics and clinical diagnostics, announced today that it has entered into a collaborative research agreement with the University of Pittsburgh Cancer Institute (UPCI). Under the agreement, Clinical Data, acting as the study sponsor, will apply metabolomics analysis to serum samples from a population of patients diagnosed with lung cancer and matched control subjects without lung cancer recruited as part of the National Cancer Institute (NCI)-funded Specialized Program of Research Excellence (SPORE) in Lung Cancer at the UPCI. The serum samples will be provided to Clinical Data by the UPCI.
